Home

Wednesday, July 30, 2014

WTC2014 | A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) + Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients


WTC2014 | A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) + Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients

WTC2014 | A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) + Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients

Powered by EventPilot



Enviado desde mi iPad
Shared by Unknown en 10:45 AM

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)